Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Romilia Gold
- Development stage
- Phase 4
- Lead developer
- Primus Remedies
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Romilia Gold is a fixed-dose combination capsule containing rosuvastatin (10 mg), clopidogrel (75 mg), and aspirin (75 mg). Developed and marketed by Primus Remedies, it is indicated for the secondary prevention of cardiovascular events, such as heart attacks and strokes, in patients with established coronary artery disease, acute coronary syndrome, or angina. Rosuvastatin is an HMG-CoA reductase inhibitor that lowers low-density lipoprotein (LDL) cholesterol and stabilizes arterial plaques. Clopidogrel and aspirin are antiplatelet agents that work synergistically through distinct pathways to inhibit platelet aggregation and prevent the formation of harmful blood clots. This triple-action therapy simplifies treatment regimens and improves patient compliance in high-risk cardiovascular populations.
- Brand names
- Romilia Gold
- Other names
- acetylsalicylic acid + clopidogrel + rosuvastatinaspirin + clopidogrel + rosuvastatinrosuvastatin + clopidogrel + aspirin
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)P2Y12 (Purinergic P2Y12 receptor)
Beyond the preview
Go deeper on Romilia Gold.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Romilia Gold.